NANJING, China, Oct. 27 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2010 on Thursday, November 11, 2010, before the market opens in the United States. Simcere’s management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 11 at 9 p.m.Beijing/Hong Kong time).
To access the conference call, please dial: | ||
United States toll-free: | +1.866.831.6291 | |
International: | +1.617.213.8860 | |
North China toll-free: | 10.800.152.1490 | |
South China toll-free: | 10.800.130.0399 | |
China toll free / Netcom: | 10.800.852.1490 | |
Hong Kong: | +852.3002.1672 | |
Please ask to be connected to Q3 2010 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 18468376
Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the “Investor Relations” section of the company’s web site at www.simcere.com.
Following the earnings conference call, an archive of the call will be available by dialing: | ||
United States toll-free: | +1.888.286.8010 | |
International: | +1.617.801.6888 | |
The passcode for replay participants is: 16680817.The telephone replay also will be archived on the “Investor Relations” section of the company’s web site for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts: | |
Email: ir@simcere.com | |
In Nanjing: | |
Frank Zhao | |
Chief Financial Officer | |
Simcere Pharmaceutical Group | |
Tel: +86-25-8556-6666 ext 8818 | |
In Beijing: | |
Ruirui Jiang | |
Brunswick Group | |
Tel: +86-10-6566-2256 | |
In the United States: | |
Kate Tellier | |
Brunswick Group | |
Tel: +1-212-333-3810 | |
In Hong Kong: | |
Joseph Lo Chi-Lun | |
Brunswick Group | |
Tel: +852-3512-5000 | |
SOURCE Simcere Pharmaceutical Group
